IVF Reads / Thin Endometrium: What a Lining Under 7 mm Means for IVF
Thin Endometrium: What a Lining Under 7 mm Means for IVF

A thin endometrium is usually defined as a lining under 7 mm (some studies use 8 mm), measured on the day of the trigger injection in a fresh IVF cycle or before progesterone starts in a frozen cycle. In 44,477 Canadian embryo transfers (Liu et al., Human Reproduction 2018), live birth per fresh transfer was 33.7% at 8 mm or more, 24.6% per transfer at 6 to 6.9 mm and 18.1% per transfer at 5 to 5.9 mm; per frozen transfer it was 28.4% at 8 mm or more and 21.2% at 4 to 4.9 mm. ESHRE's 2023 recommendations say the first steps are to re-measure and review the oestradiol regimen, with hysteroscopy for adhesions an option; ESHRE's 2023 add-ons recommendations do not recommend intrauterine PRP, G-CSF, stem cell therapy or endometrial scratching.
- Liu et al. (Human Reproduction 2018; 24,363 fresh and 20,114 frozen transfers, 33 Canadian clinics): live birth per fresh transfer fell with each millimetre below 8 mm (33.7% at 8 mm or more, 25.5% at 7-7.9 mm, 24.6% at 6-6.9 mm, 18.1% at 5-5.9 mm) and per frozen transfer below 7 mm (28.4% at 8 mm or more, 23.7% at 6-6.9 mm, 21.2% at 4-4.9 mm). 96% of transfers had a lining of 7 mm or more.
- Kasius et al. (Human Reproduction Update 2014, 22 studies, 10,724 cycles): a lining of 7 mm or less occurred in 2.4% of cycles; clinical pregnancy was 23.3% versus 48.1% above 7 mm, but thickness had 'virtually absent' ability to discriminate who would conceive, and the authors found cancelling or freezing all embryos on thickness alone not justified.
- ESHRE good practice recommendations on recurrent implantation failure (Human Reproduction Open 2023): re-assessment of endometrial thickness is recommended; a review of the oestradiol regimen is recommended if the lining remains thin; hysteroscopy to rule out Asherman's syndrome can be considered.
- Cochrane review of platelet-rich plasma (Vaidakis 2024, 12 trials, 1,069 women): in the one trial at low risk of bias, live birth odds ratio 1.10 (95% CI 0.38 to 3.14, 94 women). ESHRE 2023 does not recommend intrauterine PRP; the UK HFEA rates it red for thin endometrium. One PRP trial cited by both was retracted in 2026.
- Cochrane review of G-CSF (Kamath 2020, 15 trials, 1,253 women): no trial reported live birth; in women with a thin lining, clinical pregnancy risk ratio 1.58 (95% CI 0.95 to 2.63, 4 trials, 206 women). ESHRE 2023: intrauterine G-CSF not recommended.
Is a 6 mm lining too thin for an embryo transfer?
Not automatically. A lining under 7 mm is linked to a lower chance of a baby per transfer, and the chance falls further with each millimetre, but there is no thickness below which pregnancy stops happening. The decision is a trade-off, not a pass-fail test.
The largest dataset is a Canadian registry of 44,477 transfers from 33 clinics (Liu 2018). In fresh cycles, live birth per transfer was 33.7% at 8 mm or more and 25.5% at 7 to 7.9 mm; below that it was 24.6% per transfer at 6 to 6.9 mm and 18.1% per transfer at 5 to 5.9 mm. In frozen cycles the drop started lower: 28.4% at 8 mm or more, 27.4% at 7 to 7.9 mm, 23.7% at 6 to 6.9 mm, and 21.2% in 33 transfers at 4 to 4.9 mm. A 2025 meta-analysis of 67 studies found the same gradient and concluded that thickness predicts outcome on a sliding scale rather than offering 'a critical threshold below which ET [embryo transfer] should be avoided' (Pérez-Milán 2025).
Thin linings are uncommon. Across 22 studies, a lining of 7 mm or less turned up in 2.4% of 10,724 cycles (Kasius 2014); in the Canadian registry 96% of transfers were at 7 mm or more. The measurement is taken on the day of the trigger injection in a fresh cycle, or before progesterone starts in a frozen cycle, and machines and techniques are not standardised between clinics (Liu 2018).
Why would the lining stay thin?
Sometimes there is a structural reason, sometimes a treatment reason, and sometimes none is found; the sources retrieved for this page do not give a reliable figure for how often each applies. The causes with the clearest support:
- Scarring inside the uterus (intrauterine adhesions, or Asherman's syndrome). The basal layer of the lining is damaged, most often by curettage of a recently pregnant uterus, sometimes by hysteroscopic surgery or uterine artery embolisation. Scanty periods are a typical sign (Dreisler 2019).
- Genital tuberculosis. This matters more in India than in the countries most IVF data come from. A review by researchers at ICMR's National Institute for Research in Tuberculosis notes that it involves the lining as well as the tubes, can scar the uterine cavity, and that conception rates stay low even after full anti-TB treatment (Grace 2017).
- Not enough oestrogen exposure in a medicated frozen cycle. ESHRE's 2023 recommendations name making sure the lining gets sufficient oestradiol, by adding patches or vaginal treatment to tablets, as 'the mainstay of management'.
If you have also had low oestrogen levels outside treatment, see low oestrogen and fertility.
What should be checked before anything is added?
The inexpensive things first. ESHRE's 2023 recommendations, written for repeated failed transfers but the most specific guidance retrieved on a thin lining, say: re-measure the lining (recommended); if it stays thin, review the oestradiol regimen (recommended); and if it is still thin after that, a hysteroscopy to look for adhesions 'can be considered'. A hysteroscopy is also how adhesions are confirmed and divided (Dreisler 2019). For what that procedure involves, see hysteroscopy in the infertility work-up; for the biopsy that looks for a low-grade infection of the lining, chronic endometritis after failed transfers.
If tuberculosis is a possibility, a single test is rarely enough: Grace 2017 describes diagnosis as needing a combination of investigations, including a sample of the lining. Anti-TB treatment is a full multidrug course and should follow a confirmed diagnosis.
Should the transfer be cancelled if the lining is thin?
Thickness alone is a weak reason. The 2014 meta-analysis found that thickness had 'virtually absent' ability to tell apart who would and would not conceive, and that using it to cancel a cycle, freeze all embryos or stop IVF 'seems not to be justified' (Kasius 2014). After adjusting for age and egg numbers in 1,401 women, Griesinger 2018 estimated that 2 mm more lining would raise a 20% chance of live birth by about 1.6 percentage points. In 959 single transfers of chromosomally tested (euploid) frozen embryos, the lining showed no threshold and no independent effect on live birth (Ata 2023).
That does not make a thin lining irrelevant. It means the honest conversation is about your age, how many embryos you have, and whether waiting for another cycle with a changed oestrogen plan is likely to gain more than it costs. Ask the clinic what it expects your chance per transfer to be at today's measurement, and what it expects to change by waiting.
Do PRP, G-CSF, sildenafil, stem cells or scratching help a thin lining?
None has shown a reliable increase in live births in trials at low risk of bias, and ESHRE's 2023 add-ons recommendations list each as not recommended. Small trials often report a thicker lining or more positive pregnancy tests; that is not the same as more babies.
- Platelet-rich plasma (PRP) infused into the uterus. Cochrane (Vaidakis 2024) found 12 trials of 1,069 women and only one at low risk of bias: live birth odds ratio 1.10 (95% CI 0.38 to 3.14) in 94 women. The two trials in women with a thin lining compared PRP with G-CSF and showed no clear difference between them. A 2024 meta-analysis of eight thin-lining trials reported more live births (risk ratio 2.46) without restricting to low-bias trials (Liu 2024). ESHRE flagged a 'possible overrepresentation of one research group' in the PRP data, and one of that group's trials was retracted in 2026. HFEA: red for thin or refractory endometrium.
- G-CSF infused into the uterus. Cochrane (Kamath 2020): 15 trials, none reporting live birth; for women with a thin lining, clinical pregnancy risk ratio 1.58 (95% CI 0.95 to 2.63; 4 trials, 206 women), low-quality evidence. ESHRE: not recommended. A positive G-CSF trial that ESHRE cited was retracted in 2024.
- Sildenafil. A 2020 meta-analysis of nine studies (1,452 women) found the lining about 1.2 mm thicker and more clinical pregnancies, but its pregnancy data mixed IUI and ovulation-induction cycles and it could pool no live-birth result (Li 2020). ESHRE does not recommend sildenafil before or during ovarian stimulation and notes 'serious safety concerns'.
- Stem cell therapy. ESHRE 2023 found no randomised or comparative studies for thin endometrium, noted serious safety concerns, and does not recommend it. A 2026 review pooled 18 small studies of 323 women and said efficacy must be confirmed 'before it can be presented to the public or recommended' (Adamyan 2026).
- Endometrial scratching. Not studied specifically for thin linings. Across IVF patients, the eight low-bias trials give a live-birth odds ratio of 1.12 (95% CI 0.98 to 1.28) (Perera 2026). ESHRE: not recommended for routine use.
For how these add-ons are priced and sold, see IVF add-ons and the randomised trials; for the scratching trials in detail, endometrial scratching.
What the evidence does not establish
- A safe minimum. No retrieved study identifies a thickness below which transfer should never happen; very few transfers below 5 mm have been studied (fewer than 1% of transfers in the Canadian registry).
- Whether the thin lining causes the lower success, or marks something else. Liu 2018 lacked data beyond age, and thin linings may go with poorer ovarian response.
- That postponing a transfer to wait for a thicker lining improves the outcome. No retrieved trial randomised women to transfer now versus later.
- That any add-on raises live births in women with a thin lining. The positive results come from small trials at high risk of bias, and at least two trials in this literature have been retracted.
- Long-term safety of PRP, G-CSF or stem cells in the uterus. ESHRE notes no safety evidence on embryos exposed to PRP.
- Anything specific to India beyond tuberculosis. No ICMR guidance on thin endometrium and no Indian controlled outcome series was retrieved for this page.
What happens next?
Usually: a repeat measurement, a change to the oestrogen plan, and if the lining still does not respond, a hysteroscopy to look for scarring, with treatment of anything it finds. If nothing is found, a transfer at a modestly thin lining is still a reasonable option to discuss; the Canadian authors wrote that 'reasonable outcomes were obtained even with lower endometrial thickness measurements'.
Being told the lining is not ready, sometimes cycle after cycle, is exhausting, and it is easy to say yes to whatever is offered next. Asking what each step is expected to change, and on what evidence, is a fair question at every stage. If transfers have already failed, see when failed transfers are bad luck and when to investigate and what is worth investigating after a failed cycle.
Been offered PRP or another lining treatment?
Upload your scan reports and cycle history. IVY will set them against the ESHRE 2023 recommendations and show what the trials behind each offer found.
Keep reading
20 Sources
- Liu KE, Hartman M, Hartman A, Luo ZC, Mahutte N. The impact of a thin endometrial lining on fresh and frozen-thaw IVF outcomes: an analysis of over 40 000 embryo transfers. Hum Reprod. 2018;33(10):1883-1888. Full text read: Tables I and IV, methods (measurement timing), limitations. Human Reproduction (PMC)
- Kasius A, Smit JG, Torrance HL, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(4):530-541. Human Reproduction Update (PubMed)
- Pérez-Milán F, Caballero-Campo M, Carrera-Roig M, et al. Impact of endometrial thickness on reproductive outcome in fresh and frozen-thawed embryo transfer: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2025;66(3):271-281. Ultrasound in Obstetrics & Gynecology (PubMed)
- Gallos ID, Khairy M, Chu J, et al. Optimal endometrial thickness to maximize live births and minimize pregnancy losses: analysis of 25,767 fresh embryo transfers. Reprod Biomed Online. 2018;37(5):542-548. Reproductive BioMedicine Online (PubMed)
- Griesinger G, Trevisan S, Cometti B. Endometrial thickness on the day of embryo transfer is a poor predictor of IVF treatment outcome. Hum Reprod Open. 2018;2018(1):hox031. Human Reproduction Open (PubMed)
- Ata B, Liñán A, Kalafat E, et al. Effect of the endometrial thickness on the live birth rate: insights from 959 single euploid frozen embryo transfers without a cutoff for thickness. Fertil Steril. 2023;120(1):91-98. Fertility and Sterility (PubMed)
- Moshkalova G, Karibayeva I, Kurmanova A, et al. Endometrial thickness and live birth rates after IVF: a systematic review. Acta Biomed. 2023;94(3):e2023152. Acta Biomedica (PMC)
- ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de los Santos MJ, Griesinger G, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. Full text read: 'Re-assessment of endometrial thickness' section and recommendations. Human Reproduction Open (ESHRE)
- ESHRE Add-ons working group; Lundin K, Bentzen JG, Bozdag G, et al. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod. 2023;38(11):2062-2104. Full text read: PRP, G-CSF, endometrial scratching, stem cell therapy and adjuncts during ovarian stimulation. Human Reproduction (ESHRE)
- Human Fertilisation and Embryology Authority. Platelet-rich plasma (PRP): intrauterine infusion rated red for patients with thin or refractory endometrium. Accessed 3 November 2026. Human Fertilisation and Embryology Authority (UK)
- Vaidakis D, Papapanou M, Siristatidis CS. Autologous platelet-rich plasma for assisted reproduction. Cochrane Database Syst Rev. 2024;4:CD013875. Cochrane Database of Systematic Reviews (PubMed)
- Liu X, Qian C, Jiang X, et al. Efficacy of platelet-rich plasma in the treatment of thin endometrium: a meta-analysis of randomized controlled trials. BMC Pregnancy Childbirth. 2024;24(1):567. BMC Pregnancy and Childbirth (PMC)
- Retraction Statement: The effects of autologous platelet-rich plasma in repeated implantation failure: a randomized controlled trial. Hum Fertil (Camb). 2026;29(1):2731720 (retracts Nazari et al. 2020, PMID 30714427). Human Fertility (PubMed)
- Kamath MS, Kirubakaran R, Sunkara SK. Granulocyte-colony stimulating factor administration for subfertile women undergoing assisted reproduction. Cochrane Database Syst Rev. 2020;1:CD013226. Cochrane Database of Systematic Reviews (PubMed)
- Retraction note to: Torky H, et al. Effect of intra uterine granulocyte colony stimulating factor vs. human chorionic gonadotropin at ovum pick up day on pregnancy rate in IVF/ICSI cases with recurrent implantation failure. JBRA Assist Reprod. 2024;28(3):526 (retracts PMID 34786904; authors could not provide raw data). JBRA Assisted Reproduction (PubMed)
- Li X, Luan T, Zhao C, et al. Effect of sildenafil citrate on treatment of infertility in women with a thin endometrium: a systematic review and meta-analysis. J Int Med Res. 2020;48(11):300060520969584. Journal of International Medical Research (PMC)
- Adamyan L, Pivazyan L, Yurkanova M, et al. Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2026;319:114949. European Journal of Obstetrics & Gynecology and Reproductive Biology (PubMed)
- Perera AK, Gan J, Afroz A, et al. Endometrial injury in women undergoing in vitro fertilisation (IVF). Cochrane Database Syst Rev. 2026;5:CD009517 (update of Lensen 2021). Cochrane Database of Systematic Reviews (PubMed)
- Dreisler E, Kjer JJ. Asherman's syndrome: current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-198. International Journal of Women's Health (PMC)
- Grace GA, Devaleenal DB, Natrajan M. Genital tuberculosis in females. Indian J Med Res. 2017;145(4):425-436 (ICMR-National Institute for Research in Tuberculosis). Indian Journal of Medical Research (PMC)
Frequently asked questions
What people ask after being told the lining is too thin.
Does a thin lining raise the risk of miscarriage?
In fresh cycles, probably somewhat. In the Canadian registry, pregnancy loss after a clinical pregnancy rose as the lining fell below 8 mm in fresh transfers, but showed no significant difference by thickness in frozen transfers (Liu 2018). A UK analysis of 25,767 fresh transfers found combined early and clinical pregnancy loss of 41.7% at 5 mm or less versus 26.5% at 10 mm (Gallos 2018). Both are observational, so other factors linked to a thin lining may explain part of the difference.
Can diet, yoga or supplements thicken the lining?
No randomised trial showing that a diet, exercise routine or supplement increases live births in women with a thin lining was retrieved for this page. ESHRE's 2023 recommendations name adjusting the oestradiol regimen as the mainstay. That does not make general health habits pointless, only that they are not a proven treatment for this.
Is PRP safe to try anyway, since it is my own blood?
Safety has barely been measured. In the Cochrane review, no trial reported pain, infection, allergic reaction or fetal abnormality, and one trial of 120 women found more preterm births after intrauterine PRP (odds ratio 8.02, 95% CI 1.72 to 37.33, low certainty). ESHRE notes there is no safety evidence on embryos exposed to PRP in the uterus, and the HFEA cites 'potential safety concerns' in rating it red.
Should I be tested for genital tuberculosis?
It is worth raising if you have had TB before, have scanty periods, or have tubal damage on an HSG, because genital TB can scar the uterine lining (Grace 2017). Diagnosis usually needs more than one test, including a sample of the lining. Ask what test is proposed and what result would lead to treatment, since anti-TB treatment is a long multidrug course.


